JPWO2020210067A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020210067A5 JPWO2020210067A5 JP2021559535A JP2021559535A JPWO2020210067A5 JP WO2020210067 A5 JPWO2020210067 A5 JP WO2020210067A5 JP 2021559535 A JP2021559535 A JP 2021559535A JP 2021559535 A JP2021559535 A JP 2021559535A JP WO2020210067 A5 JPWO2020210067 A5 JP WO2020210067A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- polypeptide sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims description 438
- 210000004027 cells Anatomy 0.000 claims description 56
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 50
- 239000000427 antigen Substances 0.000 claims description 44
- 102000038129 antigens Human genes 0.000 claims description 44
- 108091007172 antigens Proteins 0.000 claims description 44
- 229920000023 polynucleotide Polymers 0.000 claims description 31
- 239000002157 polynucleotide Substances 0.000 claims description 31
- 201000011510 cancer Diseases 0.000 claims description 25
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 21
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 21
- 102100013694 DLL3 Human genes 0.000 claims description 18
- 101700003144 DLL3 Proteins 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 150000007523 nucleic acids Chemical group 0.000 claims description 13
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims description 12
- 206010018338 Glioma Diseases 0.000 claims description 12
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims description 12
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims description 12
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 12
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 12
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims description 12
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 12
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims description 12
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 210000000822 Killer Cells, Natural Anatomy 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 6
- 206010017758 Gastric cancer Diseases 0.000 claims description 6
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 6
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims description 6
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims description 6
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims description 6
- 210000003932 Urinary Bladder Anatomy 0.000 claims description 6
- 201000010881 cervical cancer Diseases 0.000 claims description 6
- 201000010536 head and neck cancer Diseases 0.000 claims description 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 201000009251 multiple myeloma Diseases 0.000 claims description 6
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 6
- 230000000955 neuroendocrine Effects 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims description 5
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 229940079593 drugs Drugs 0.000 claims description 5
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims description 4
- 210000004693 NK cell Anatomy 0.000 claims description 4
- 210000001744 T-Lymphocytes Anatomy 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 231100000486 side effect Toxicity 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000002463 transducing Effects 0.000 claims description 3
- 108010071919 Bispecific Antibodies Proteins 0.000 claims description 2
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 102000004965 antibodies Human genes 0.000 claims description 2
- 108090001123 antibodies Proteins 0.000 claims description 2
- 230000000711 cancerogenic Effects 0.000 claims description 2
- 230000000139 costimulatory Effects 0.000 claims description 2
- 230000009089 cytolysis Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000031146 intracellular signal transduction Effects 0.000 claims description 2
- 230000004068 intracellular signaling Effects 0.000 claims description 2
- 230000002934 lysing Effects 0.000 claims description 2
- 230000001404 mediated Effects 0.000 claims description 2
- 230000001502 supplementation Effects 0.000 claims description 2
- 210000004881 tumor cells Anatomy 0.000 claims description 2
- 206010024324 Leukaemias Diseases 0.000 claims 3
- 230000001684 chronic Effects 0.000 claims 3
- 230000000527 lymphocytic Effects 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000002955 isolation Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962830598P | 2019-04-08 | 2019-04-08 | |
| US62/830,598 | 2019-04-08 | ||
| US201962861377P | 2019-06-14 | 2019-06-14 | |
| US62/861,377 | 2019-06-14 | ||
| US201962896790P | 2019-09-06 | 2019-09-06 | |
| US62/896,790 | 2019-09-06 | ||
| US201962928615P | 2019-10-31 | 2019-10-31 | |
| US62/928,615 | 2019-10-31 | ||
| PCT/US2020/025643 WO2020210067A1 (en) | 2019-04-08 | 2020-03-30 | Humanized anti-dll3 chimeric antigen receptors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022526420A JP2022526420A (ja) | 2022-05-24 |
| JPWO2020210067A5 true JPWO2020210067A5 (es) | 2022-06-15 |
Family
ID=72750831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559535A Pending JP2022526420A (ja) | 2019-04-08 | 2020-03-30 | ヒト化抗ｄｌｌ３キメラ抗原受容体及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220184127A1 (es) |
| EP (1) | EP3952888A1 (es) |
| JP (1) | JP2022526420A (es) |
| KR (1) | KR20210150432A (es) |
| CN (1) | CN113795262A (es) |
| AU (1) | AU2020271012A1 (es) |
| BR (1) | BR112021016272A2 (es) |
| CA (1) | CA3132202A1 (es) |
| IL (1) | IL286984A (es) |
| MX (1) | MX2021012336A (es) |
| SG (1) | SG11202108759SA (es) |
| WO (1) | WO2020210067A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102509648B1 (ko) * | 2019-08-06 | 2023-03-15 | 아프리노이아 테라퓨틱스 리미티드 | 병리학적 타우 종에 결합하는 항체 및 이의 용도 |
| JP2024514855A (ja) * | 2021-05-08 | 2024-04-03 | 上海齊魯制藥研究中心有限公司 | Ｄｌｌ３に対する結合分子及びその使用 |
| CN114790240B (zh) * | 2022-06-10 | 2023-06-06 | 郑州大学 | SARS-CoV-2中和性单克隆抗体及应用 |
| WO2024044779A2 (en) * | 2022-08-26 | 2024-02-29 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3) |
| CN116813784B (zh) * | 2023-05-17 | 2024-03-01 | 星奕昂(上海)生物科技有限公司 | 靶向dll3的抗体及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2466669T3 (es) * | 2006-10-02 | 2014-06-10 | Regeneron Pharmaceuticals, Inc. | Anticuerpos humanos con alta afinidad para el receptor IL-4 humano |
| AU2010303443A1 (en) * | 2009-10-09 | 2012-04-19 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-Her 3 antibodies |
| PT2530091T (pt) * | 2010-01-29 | 2018-05-17 | Chugai Pharmaceutical Co Ltd | Anticorpo anti-dll3 |
| US9090674B2 (en) * | 2010-05-17 | 2015-07-28 | The Board Of Regents Of The University Of Texas System | Rapid isolation of monoclonal antibodies from animals |
| WO2012019061A2 (en) * | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
| EP2739305A1 (en) * | 2011-08-05 | 2014-06-11 | IFOM Fondazione Istituto Firc di Oncologia Molecolare | Constitutively active upar variants and their use for the generation and isolation of inhibitory antibodies |
| RS56443B1 (sr) * | 2012-02-24 | 2018-01-31 | Abbvie Stemcentrx Llc | Ddl3 modulatori i postupci primene |
| CN103173413A (zh) * | 2012-12-07 | 2013-06-26 | 天津三箭生物技术有限公司 | 小鼠抗人β-Catenin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 |
| GB201302447D0 (en) * | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| US9879087B2 (en) * | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| MA41613A (fr) * | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
| TWI793062B (zh) * | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| BR112020005938A2 (pt) * | 2017-09-27 | 2020-11-17 | University Of Southern California | célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso |
-
2020
- 2020-03-30 JP JP2021559535A patent/JP2022526420A/ja active Pending
- 2020-03-30 AU AU2020271012A patent/AU2020271012A1/en not_active Abandoned
- 2020-03-30 WO PCT/US2020/025643 patent/WO2020210067A1/en unknown
- 2020-03-30 KR KR1020217034403A patent/KR20210150432A/ko unknown
- 2020-03-30 BR BR112021016272A patent/BR112021016272A2/pt not_active Application Discontinuation
- 2020-03-30 EP EP20788157.4A patent/EP3952888A1/en not_active Withdrawn
- 2020-03-30 US US17/593,087 patent/US20220184127A1/en active Pending
- 2020-03-30 CN CN202080027518.8A patent/CN113795262A/zh active Pending
- 2020-03-30 CA CA3132202A patent/CA3132202A1/en active Pending
- 2020-03-30 SG SG11202108759S patent/SG11202108759SA/en unknown
- 2020-03-30 MX MX2021012336A patent/MX2021012336A/es unknown
-
2021
- 2021-10-05 IL IL286984A patent/IL286984A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI564306B (zh) | 雙特異性抗體 | |
| US7498142B2 (en) | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies | |
| JP6359372B2 (ja) | ＤＡＲＰｉｎを含む二重特異キメラ蛋白質 | |
| WO2019042119A1 (zh) | 抗人cd47抗体及其用途 | |
| JP2022087341A (ja) | 抗クローディン１８．２抗体およびその使用 | |
| JPWO2019173420A5 (es) | ||
| JP2019531084A5 (es) | ||
| JP2020528750A5 (es) | ||
| JP2018524284A (ja) | 抗ｒｏｒ１抗体 | |
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2009545325A5 (es) | ||
| WO2012076066A1 (en) | Anti-ror1 antibodies and uses thereof | |
| JP2013527761A5 (es) | ||
| JP2022513053A (ja) | Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用 | |
| TWI821474B (zh) | Ｃｄ３抗體及其藥物用途 | |
| TW202033218A (zh) | 多特異性蛋白分子 | |
| IL310938A (en) | Anti-CCR8 antibodies and their uses | |
| JPWO2019224711A5 (es) | ||
| CN109912716B (zh) | 一种egfr抗体及其制备方法和应用 | |
| US20150232573A1 (en) | Anti-egfr/anti-her2 bispecific antibodies with anti-egfr darpins | |
| Watanabe et al. | In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody | |
| JPWO2020210067A5 (es) | ||
| JPWO2019217145A5 (es) | ||
| JPWO2020205331A5 (es) | ||
| JPWO2020210247A5 (es) |